• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » QPS expands phase I clinic in the Netherlands

QPS expands phase I clinic in the Netherlands

November 27, 2012
CenterWatch Staff

QPS Holdings has completed a 24-bed annex to its phase I clinic at the University Medical Center Groningen in the Netherlands, bringing to 58 its bed capacity for the conduct of first-in-man and early-phase research on novel and complex therapeutic agents.

The expansion was prompted by rising demand for QPS to conduct a greater diversity of large, complex phase I studies, including single- and multiple-ascending dose trials following allometric (first) dose selection to define maximum tolerated doses in first-in-man exposures; PK/PD modeling studies to define the pharmacokinetic and metabolic characteristics of new chemical entities and biologicals; 14C mass balance trials with analysis of both "hot" and "cold" species in the on-site bioanalytical and 14C radionuclide laboratories; food-effect studies, alone or combined with single-ascending dose trials; BA/BE studies for formulation development, generic comparison or pivotal confirmation of a final formulation; drug-drug interaction trials; in-vitro/in-vivo comparisons (IVIVC); and phase Ib/IIa patient studies using clinical endpoint/proof-of-concept in common therapeutic areas and particularly in early pharmacodynamic profiling of CNS compounds (imaging and continuous CSF sampling), respiratory agents (bronchoprovocation challenge testing) and gynecological products (transvaginal ultrasound).

"In the Netherlands, where regulatory timeframes are fast and reliable for phase I studies, client demand is growing. For tight schedules, the Netherlands CTA approval timelines of 14 days are very attractive," said Dr. Wim Tamminga, division director, clinical pharmacology for QPS Netherlands.

QPS also offers IND and NDA program partnering. It employs more than 900 at 10 sites in nine countries on four continents.

Upcoming Events

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing